Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials.

Citation metadata

From: Chinese Journal of Integrative Medicine(Vol. 27, Issue 10)
Publisher: Springer
Document Type: Report; Brief article
Length: 340 words

Document controls

Main content

Abstract :

Keywords: Chinese herbal medicine; systemic lupus erythematous; systematic review and meta-analysis; randomized controlled trials Abstract Objective To provide evidence on the efficacy and safety of Chinese herbal medicine (CHM) as interventions for systemic lupus erythematosus (SLE). Methods Seven electronic databases, including the Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Chinese Biomedical Literature Service System (SinoMed), Wanfang, Embase, and PubMed, were comprehensively searched, from their inception to August 16, 2020, for all randomized controlled trials (RCTs) that focused on CHM used alone or in combination with conventional medicine for SLE. Outcomes were SLE activity index (SLEDAI), traditional Chinese medicine symptom/syndrome score (TCMSS), dosage of glucocorticoids, main serological testing, and incidence of adverse events. Data were extracted and pooled using Review Manager 5.3 software. Results A total of 13 RCTs enrolling 856 participants met our inclusion criteria. Meta-analyses showed that, compared to placebo, CHM had statistically significant effect on reducing SLEDAI score (MD=-1.74, 95% CI: -2.29 to -1.18), diminishing TCMSS (SMD=-0.89, 95% CI: -1.16 to -0.62), decreasing dosage of glucocorticoids (MD=-2.41 mg/d, 95% CI: -3.34 to -1.48), lowering erythrocyte sedimentation rate (MD=-4.78 mm/h, 95% CI: -8.86 to -0.71), and increasing serum complement C4 level (MD=0.03 mg/dL, 95% CI: 0.00 to 0.06). No significant difference was found between CHM and placebo on adverse events. Conclusions CHM provided significant beneficial effect on controlling disease activity and reducing dose of glucocorticoids used among SLE patients. Future advanced designed RCTs for CHM treating moderate to severe SLE with multicenter and longer follow-up are urgently needed. Author Affiliation: (1) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 100029, Beijing, China (2) Department of Internal Medicine, Yale University School of Medicine, 06520, New Haven, Connecticut, USA (3) Department of Rheumatology, the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, 310005, Hangzhou, China (f) liujp@bucm.edu.cn Article History: Registration Date: 07/27/2021 Accepted Date: 12/21/2020 Online Date: 07/28/2021 Byline: Ying Wang (1, 2), Mei Han (1), Christopher E. Pedigo (2), Zhi-min Xie (3), Wei-jie Wang (3), Jian-ping Liu (corresponding author) (1, f)

Source Citation

Source Citation   

Gale Document Number: GALE|A681422111